Fig. 3.

(A) Lanatoside C upregulates DR5 on GBM cells. U87 cells were treated with 0.25 or 1 µM of lanatoside C. Sixteen hours later, cells were labeled with anti DR4- or DR5-PE–conjugated antibodies followed by FACS analysis. Data are shown as mean fluorescence intensity (MFI) ± standard deviation. (B) U87-Gluc-CFP cells were pretreated with tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–R2-Fc chimeric protein (300 ng/mL) followed by lanatoside C in the presence or absence of TRAIL. Cell viability was assayed using CellTiter-Glo 24 h later. Data are presented as the percentage of cell viability in treated versus untreated samples and are shown as the mean of biological triplicates ± standard deviation.